Bank of America
ALGS icon

Bank of America’s Aligos Therapeutics ALGS Stock Holding History

Bank of America’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-229,754
Closed -$1.71M – 5671
2026
Q1 		$1.71M Buy
229,754
+216,646
+1,653% +$1.64M ﹤0.01% 4216
2025
Q4 		$122K Buy
13,108
+11,194
+585% +$106K ﹤0.01% 5548
2025
Q3 		$18.8K Sell
1,914
-698
-27% -$6.38K ﹤0.01% 7078
2025
Q2 		$18.8K Sell
2,612
-151,891
-98% -$909K ﹤0.01% 7071
2025
Q1 		$1.27M Buy
154,503
+154,218
+54,112% +$3.38M ﹤0.01% 5058
2024
Q4 		$11.4K Sell
285
-6,566
-96% -$127K ﹤0.01% 6948
2024
Q3 		$59.3K Sell
6,851
-25,790
-79% -$321K ﹤0.01% 6497
2024
Q2 		$286K Sell
32,641
-13,268
-29% -$233K ﹤0.01% 5693
2024
Q1 		$1.12M Sell
45,909
-1
-0% -$20 ﹤0.01% 4863
2023
Q4 		$762K Sell
45,910
-99
-0.2% -$1.7K ﹤0.01% 5189
2023
Q3 		$859K Sell
46,009
-29
-0.1% -$643 ﹤0.01% 4926
2023
Q2 		$1.12M Buy
46,038
+127
+0.3% +$3.41K ﹤0.01% 4697
2023
Q1 		$1M Sell
45,911
-95
-0.2% -$3.63K ﹤0.01% 4894
2022
Q4 		$1.09M Buy
46,006
+80
+0.2% +$2.02K ﹤0.01% 4778
2022
Q3 		$1.26M Buy
45,926
+415
+0.9% +$13.8K ﹤0.01% 4690
2022
Q2 		$1.38M Sell
45,511
-1,859
-4% -$63.1K ﹤0.01% 4621
2022
Q1 		$2.55M Buy
47,370
+798
+2% +$63.9K ﹤0.01% 4351
2021
Q4 		$13.8M Buy
46,572
+45,223
+3,352% +$16.5M ﹤0.01% 2597
2021
Q3 		$522K Buy
1,349
+679
+101% +$269K ﹤0.01% 5610
2021
Q2 		$341K Sell
670
-110
-14% -$70.1K ﹤0.01% 5707
2021
Q1 		$444K Buy
780
+436
+127% +$290K ﹤0.01% 5468
2020
Q4 		$237K Buy
+344
New +$168K ﹤0.01% 5490

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America's ALGS Position: Q2 2026 in Review

Bank of America sold out of Aligos Therapeutics (ALGS) in Q2 2026, closing a stake of 229,754 shares — an estimated $1.71M sold.

Bank of America first reported a position in ALGS in Q4 2020 and held it in 22 quarters. The position peaked at $13.8M in Q4 2021. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

  • Bank of America reported no remaining Aligos Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Bank of America sold 229,754 Aligos Therapeutics shares in Q2 2026, an estimated $1.71M.
  • Bank of America first reported a position in Aligos Therapeutics in Q4 2020 and held it in 22 quarters.
  • Bank of America's Aligos Therapeutics position peaked at $13.8M in Q4 2021.
  • 31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.